Description
| Description | RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease. |
| Targets&IC50 | BD2:0.51 μM |
| Cell Research | RVX-208 is prepared in DMSO and stored, and then diluted with appropriate medium before use[2]. Huh7 cells are plated at 23,000/well in a 96 well plate in DMEM+10% FBS before allowing to grow overnight. Cells are treated with compounds for 48 h in 0.1% DMSO with or without 5 μM Actinomycin D. U937 cells are differentiated for 3 days in 60 ng/mL PMA, 32,000 cells/well in 96-well format. Cells are then treated with compound in 0.1% DMSO in RPMI media+10% FBS, and after 1 h, lipopolysaccharide is added to the cells at 1 μg/mL for 3 hours[2]. |
| Synonyms | RVX000222, RVX-208 |
| Molecular Weight |
370.4 |
| Formula | C20H22N2O5 |
| CAS No. | 1044870-39-4 |
Storage
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
Ethanol: <1 mg/mL
DMSO: 69 mg/mL (186.3 mM)
H2O: <1 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
